Two mutations responsible for a devastating neurological condition first identified 15 years ago have been discovered by Mayo Clinic researchers.
The researchers say their study -- appearing in Nature Genetics -- has revealed a new neural pathway that may help understand a variety of similar conditions.
VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Christopher Klein, are available on the Mayo Clinic News Blog. The password for this post is HSAN1.
Called hereditary sensory and autonomic neuropathy type 1 (HSAN1) with dementia and hearing loss, its symptoms begin to appear in the young adult years -- 20 to 35 -- after which an individual''s cognitive ability, hearing and ability to sense limbs deteriorate slowly. There is no treatment or cure. It was first identified and described by Peter Dyck, M.D., a senior Mayo neurologist and co-author of this current paper.
In addition to the original family studied by Dr. Dyck, Dr. Klein''s team focused on DNA samples and data from three other family groups spanning the United States, Japan, the United Kingdom (U.K.) and Australia (the U.K. and Australian individuals are one family and the other U.S. family makes up the four). In addition to NextGen sequencing and subsequent bioinformatics studies, team members conducted intracellular and methylation studies. Ultimately, they discovered the mutations on the DNMT1 area cause misfolding of the enzyme, decreased enzyme activity and loss of chromatin binding. They also showed that even moderate alterations in methylation can disrupt normal neural functions, "suggesting that DNMT1 is part of a precise mechanism of dynamic regulation of the nervous system."
Because the condition worsens with age, the researchers say its effect is cumulative and epigenetic. That is, it directly alters the genome after birth.
While the findings offer no immediate treatment for the affected families, the discovery does provide a much greater understanding of how the disease functions, and directions for future research in neurodegeneration.
The study was funded by the National Institutes of Health and the Muscular Dystrophy Association. The collaborators include Maria-Victoria Botuyan, Ph.D.; Yanhong Wu; Christopher Ward M.B., Ch.B., Ph.D.; Julie Cunningham, Ph.D.; Glenn Smith, Ph.D.; Elizabeth Atkinson; Sumit Middha; William Litchy, M.D.; James Dyck, M.D.; Joseph Parisi, M.D.; Lisa Boardman, M.D.; Georges Mer, Ph.D.; David Smith, Ph.D.; and Peter Dyck, M.D., the Roy E. and Merle Meyer Professor of Neuroscience; all of Mayo Clinic; Garth Nicholson, M.B.B.S., Ph.D., University of Sydney; Simon Hammans, M.D., National Health Service Trust, Southampton, U.K.; Kaori Hojo, M.D., and Hiromitch Yamanishi, M.D., Harima Sanitorium, Japan; Adam Karpf, Ph.D., Roswell Park Cancer Institute, Buffalo, N.Y.; Douglas Wallace, Ph.D., and Mariella Simon, University of California, Irvine; Cecilie Lander, M.D., Queensland Health, Herston, Australia; and Benjamin Boes, Ph.D., Roche Applied Science Genomic Sequencing, Indianapolis.
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit www.mayoclinic.org/about/ and www.mayoclinic.org/news.